Resiquimod

ArtNr	HY-13740-25mg
Hersteller	MedChem Express
CAS-Nr.	144875-48-9
Menge	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 500 mg 50 mg 5 mg
Kategorie	Oncology Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer
Typ	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Sachan S, et al. Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken. Vaccine. 2015 Aug 26;33(36):4526-32.\|[2]Brugnolo F, et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol. 2003 Feb;111(2):380-8.\|[3]Zhou ZX, et al. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus). Dev Comp Immunol. 2015 Mar;49(1):113-20.\|[4]Maki Yokogawa, et al. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus. Arthritis Rheumatol. 2014 Mar;66(3):694-706. \|[5]Manuel Keppler, et al. Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo. Front Immunol. 2023 Jun 20:14:1168252.
Smiles	OC(C)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	R848,S28463
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	HCV; Toll-like Receptor (TLR)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	314.39
Product Description	Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
Manufacturer - Research Area	Inflammation/Immunology; Cancer
Solubility	DMF: 50 mg/mL (ultrasonic)\|DMSO: 100 mg/mL (ultrasonic)\|Ethanol: 25 mg/mL (ultrasonic)\|H2O: 0.1 mg/mL (ultrasonic)\|Methanol: 25 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Immunology/Inflammation
Isoform	TLR7; TLR8
Clinical information	Phase 2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-13740-25mg-safety-datasheet.pdf